Loading…
Curis Lifesciences (CURIS)₹179.65−2.26%Pharmaceuticals
In the Mar 2026 quarter (standalone), Curis Lifesciences reported sales of ₹32.74 Cr, down 4.8% from Mar 2025, and net profit of ₹2.72 Cr, down 32.2% year on year. For the year to Mar 2026, sales were ₹60.66 Cr and net profit ₹6.94 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 15.91 | 34.39 | 27.90 | 32.74 |
| Expenses | 12.11 | 27.49 | 21.97 | 27.61 |
| Operating Profit | 3.80 | 6.92 | 5.98 | 5.13 |
| OPM % | 24.0% | 20.2% | 21.5% | 15.7% |
| Other Income | −0.01 | 0.04 | 0.00 | 0.26 |
| Interest | 0.51 | 0.62 | 0.44 | 0.72 |
| Depreciation | 0.35 | 0.35 | 0.35 | 0.36 |
| Profit before tax | 2.96 | 6.04 | 5.23 | 4.36 |
| Tax % | 25.4% | 33.6% | 19.3% | 37.6% |
| Exceptional items | −0.01 | 0.01 | 0.00 | 0.00 |
| Net Profit | 2.21 | 4.01 | 4.23 | 2.72 |
| EPS (Rs) | 44.07 | 6.75 | 7.10 | 3.36 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 23.72 | 35.24 | 35.16 | 49.18 | 60.66 |
| Expenses | 20.17 | 31.99 | 26.80 | 39.68 | 49.55 |
| Operating Profit | 3.57 | 3.25 | 8.37 | 9.53 | 11.12 |
| OPM % | 15.1% | 9.3% | 23.9% | 19.4% | 18.4% |
| Other Income | 0.01 | 0.33 | 0.30 | 0.50 | 0.26 |
| Interest | 1.63 | 1.34 | 0.86 | 1.12 | 1.15 |
| Depreciation | 0.76 | 0.74 | 0.69 | 0.68 | 0.71 |
| Profit before tax | 1.24 | 1.55 | 7.18 | 8.28 | 9.57 |
| Tax % | 59.3% | 20.1% | 32.2% | 26.2% | 27.5% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.50 | 1.24 | 4.88 | 6.13 | 6.94 |
| EPS (Rs) | 9.81 | 24.63 | 97.54 | 10.31 | 8.57 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.49 | 0.49 | 0.49 | 5.92 | 8.07 |
| Reserves | −1.41 | −0.19 | 5.38 | 10.30 | 39.35 |
| Borrowings | 17.58 | 16.15 | 17.05 | 15.57 | 21.57 |
| Other Liabilities | 10.70 | 13.20 | 10.96 | 10.76 | 12.65 |
| Total Liabilities | 27.36 | 29.65 | 33.88 | 42.55 | 81.64 |
| Fixed Assets | 12.29 | 12.17 | 11.57 | 10.96 | 10.75 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.01 | 1.32 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 15.07 | 17.48 | 22.31 | 31.58 | 69.57 |
| Inventories | 5.40 | 5.13 | 9.00 | 18.46 | 34.24 |
| Trade receivables | 6.25 | 9.49 | 10.12 | 7.53 | 11.23 |
| Cash & equivalents | 0.12 | 0.16 | 0.43 | 0.31 | 3.18 |
| Total Assets | 27.36 | 29.65 | 33.88 | 42.55 | 81.64 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 4.96 | 3.36 | 0.29 | −1.77 | −16.48 |
| Cash from investing activity | −0.36 | −0.54 | −0.05 | −0.01 | −1.58 |
| Cash from financing activity | −4.57 | −2.75 | 0.04 | 1.66 | 20.81 |
| Net cash flow | 0.00 | 0.03 | 0.26 | −0.10 | 2.85 |
| Capex | 0.39 | 0.61 | 0.06 | 0.08 | 1.79 |
| Free cash flow | 4.57 | 2.78 | 0.22 | −1.86 | −18.23 |
| CFO / OP % | 138.0% | 103.0% | 3.0% | −2.0% | −126.9% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 96 | 98 | 105 | 56 | 68 |
| Inventory days | 207 | 114 | 272 | 346 | 296 |
| Days payable | 359 | 262 | 209 | 111 | 70 |
| Cash conversion cycle | −56 | −51 | 167 | 290 | 292 |
| Working capital days | −15 | −20 | 37 | 101 | 233 |
| ROCE % | — | 17.2% | 40.6% | 34.2% | 21.2% |
For the Mar 2026 quarter, Curis Lifesciences reported sales of ₹32.74 Cr, down 4.8% year on year and net profit of ₹2.72 Cr, down 32.2% year on year. The operating margin was 15.7%.
Curis Lifesciences' sales for the year to Mar 2026 were ₹60.66 Cr.
Net profit for the year to Mar 2026 was ₹6.94 Cr. Earnings per share over the same trailing period were ₹8.57.
Curis Lifesciences reported borrowings of ₹21.57 Cr at Mar 2026, against cash and equivalents of ₹3.18 Cr.
Cash from operations was −₹16.48 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹18.23 Cr.